Does ISIS 304801 reduce triglyceride levels in patients with hypertriglyceridemia?
Antisense inhibition of APOC3 with ISIS 304801 significantly lowers triglyceride levels in patients with hypertriglyceridemia.
We found that treatment with ISIS 304801 was associated with significant lowering of triglyceride levels, among patients with a broad range of baseline levels, through selective antisense inhibition of APOC3 synthesis. (Funded by Isis Pharmaceuticals; ClinicalTrials.gov number, NCT01529424.).
Gaudet et al. (Wed,) studied this question.